{"url_path":"/sec/dmra/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-219327-index.html","accession_number":"0001193125-26-219327","cik":"0001800315","ticker":"DMRA","issuer_name":"Damora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-219327-index.html","primary_entity_key":"0001800315","primary_entity_name":"Damora Therapeutics, Inc."},"word_count":576,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\n \n\n \n\nExhibit\n\nNumber\n\nExhibit Description\n\n \n\nIncorporated by Reference\n\nHerein from Form or Schedule\n\n \n\nFiling Date\n\n \n\nSEC File /\n\nReg. Number\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n2.2†\n\n \n\n \n\n[Agreement and Plan of Merger, dated November 10, 2025, by and among the Registrant, Daylight Merger Sub I, Inc., Daylight Merger Sub II, LLC and Damora Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/d53983dex21.htm)\n\n \n\nForm 8-K\n\n(Exhibit 2.1)\n\n \n\nNovember 10, 2025\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.1\n\n[Amended and Restated Certificate of Incorporation of the Registrant.](https://www.sec.gov/Archives/edgar/data/1800315/000119312520285653/d53274dex31.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n \n\nNovember 4, 2020\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.2\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (Reverse Stock Split).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001800315/000095017024103957/glto-20240829.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n \n\nSeptember 5, 2024\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.3\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (Authorized Share Increase).](https://www.sec.gov/Archives/edgar/data/1800315/000119312526043741/glto-ex3_1.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n \n\nFebruary 10, 2026\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.4\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (Name Change).](https://www.sec.gov/Archives/edgar/data/1800315/000119312526099404/dmra-ex3_1.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n \n\nMarch 10, 2026\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.5\n\n \n\n[Certificate of Designation of Series A Non-Voting Convertible Preferred Stock.](https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/glto-ex3_1.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n \n\nOctober 7, 2024\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.6\n\n \n\n[Certificate of Designation of Series B Non-Voting Convertible Preferred Stock.](https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/d53983dex31.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n \n\nNovember 10, 2025\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.7\n\n \n\n[Certificate of Designation of Series C Non-Voting Convertible Preferred Stock.](https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/d53983dex32.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.2)\n\n \n\nNovember 10, 2025\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.8\n\n \n\n[Certificate of Correction to the Certificate of Designation of the Series C Non-Voting Convertible Preferred Stock.](https://www.sec.gov/Archives/edgar/data/1800315/000119312525312912/glto-ex3_3.htm)\n\n \n\nForm 8-K/A\n\n(Exhibit 3.3)\n\n \n\nDecember 9, 2025\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.9\n\n[Amended and Restated By-laws of the Registrant.](https://www.sec.gov/Archives/edgar/data/1800315/000119312520285653/d53274dex32.htm)\n\n \n\nForm 8-K\n\n(Exhibit 3.2)\n\n \n\nNovember 4, 2020\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n3.10\n\n \n\n[Certificate of Amendment to Amended and Restated By-laws of the Registrant.](https://www.sec.gov/Archives/edgar/data/1800315/000095017025041981/glto-ex3_5.htm)\n\n \n\nForm 10-K\n\n(Exhibit 3.5)\n\n \n\nMarch 19, 2025\n\n \n\n001-39655\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.1#\n\n \n\n[Damora Therapeutics, Inc. 2026 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1800315/000119312526117594/dmra-ex99_1.htm)\n\n \n\nForm S-8 (Exhibit 99.1)\n\n \n\nMarch 20, 2026\n\n \n\n333-294492\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.2#*\n\n \n\n[Form of Option Award Agreement under the 2026 Equity Incentive Plan.](dmra-ex10_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.3#\n\n \n\n[Damora Therapeutics, Inc. 2026 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/1800315/000119312526117594/dmra-ex99_2.htm)\n\n \n\nForm S-8 (Exhibit 99.2)\n\n \n\nMarch 20, 2026\n\n \n\n333-294492\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](dmra-ex31_1.htm).\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](dmra-ex31_2.htm).\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n69\n\n \n\n32.1*†\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](dmra-ex32_1.htm).\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL (extensible Business Reporting Language) Instance Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n* Filed herewith.\n\n# Indicates management contract or any compensatory plan, contract or arrangement.\n\n† This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent specifically incorporated by reference into such filing.\n\n \n\n70\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nDamora Therapeutics, Inc\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Jennifer Jarrett\n\nJennifer Jarrett\n\nPresident, Chief Executive Officer and Director\n\n(Principal Executive Officer)\n\n \n\nDate: May 12, 2026\n\nBy:\n\n/s/ Brian Burkavage\n\nBrian Burkavage\n\nSVP, Finance\n\n(Principal Financial and Accounting Officer)\n\n \n\n71"}